Objectives: To evaluate potential anti-biofilm agents for their ability to enhance the activity of antibiotics for local treatment of localized biofilm infections.
Introduction
Biofilms are an important cause of persistent and chronic infections such as otitis media with effusion (OME), 1, 2 prosthetic joint infections, 3 colonization of other indwelling devices 4 and infections after trauma, either following the injury itself or the surgical treatment. 5 The biofilm mode of growth has many strategies for persistence and in this state only essential processes remain active and therefore many target sites for antibiotics are downregulated leading to reduced susceptibility to antibiotics. 6, 7 Biofilm eradication requires 10-1000 times the MIC of antibiotics normally needed to inhibit the planktonic form. 8, 9 Such high levels of antibiotics would be difficult to achieve safely when administered systemically. 10 Many biofilm infections are localized, e.g. around spinal and orthopaedic implants, in trauma or in chronic wounds or facial sinuses. Local administration of antibiotics in such situations results in very high concentrations at the biofilm site while avoiding systemic exposure, but, even then, failures occur due to incomplete eradication of the biofilm.
Therefore, there is a need for alternative anti-biofilm strategies that might enable locally administered antibiotics to exert antibiofilm effect more consistently while if possible reducing the concentrations necessary. Agents that disrupt the biofilm matrix may enhance the anti-biofilm activity of antibiotics so that the biofilm cells become once again susceptible to antibiotic treatment. We identified the following agents that could potentially be 'antibiotic enhancers': N-acetylcysteine (NAC), 11, 12 acetylsalicylic acid, 13, 14 sodium salicylate, 15, 16 salicylic acid, 17, 18 recombinant human deoxyribonuclease I (rhDNase I), 19, 20 dispersin B, 21 hydrogen peroxide and Johnson's Baby Shampoo (JBS). 23 JBS was included for its reported ability to inhibit biofilm formation in vitro and to reduce clinical symptoms after local nasal application for treatment of chronic rhinosinusitis, a biofilm infection. 24 Its individual ingredients, specifically the surfactants, 25 dyes [25] [26] [27] and preservatives 28 were also investigated to determine the anti-biofilm activity of its components.
To date these agents have been studied individually in different in vitro biofilm and species models and in combination with different antimicrobial agents. However, they have not been compared against each other in a consistent model. To do this, we tested them in a systematic manner with the aim of identifying an 'antibiotic enhancer' that could be used as adjunct to antibiotics to eradicate local biofilm infections.
Methods
The antibiotic enhancers were tested against two biofilm-forming bacteria, Staphylococcus aureus and Pseudomonas aeruginosa, grown as biofilms on silicone discs. The agents were paired with rifampicin and clindamycin against S. aureus and gentamicin and ciprofloxacin against P. aeruginosa. These antibiotics were chosen based on the isolates' susceptibilities, routine clinical use and their known anti-biofilm activity.
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Biofilm model
The two strains of S. aureus and P. aeruginosa strains were isolated from clinical biofilm infections (from the middle ear effusion of patients undergoing surgery for treatment of OME). Biofilms were grown on autoclaved silicone discs (6.0 mm%1.0 mm, silicone elastomer MQ/VNQ/PMQ/PVMQ; Goodfellow Ltd, Cambridge, UK) in 20 mL volumes of tryptone soya broth (TSB; Oxoid, Basingstoke, UK). Discs were added to a 0.5 McFarland bacterial TSB suspension, spectrophotometer-verified to between 0.080 and 0.130 absorbance at 490 nm. The 0.5 McFarland suspension containing the discs at the beginning of each 'treatment' run ('treatment' in this context refers to exposure in vitro to antibiotics and/or potential enhancers) was quantified by viable counting to ensure consistency. The uninoculated control disc was added to an equal volume of TSB alone. Both groups were incubated for 1 h with shaking (200 rpm) then 1 h statically at 37 C for attachment to take place.
After incubation, each disc was added to 1.0 mL of TSB in a sterile bijou bottle and incubated for 5 days at 37 C without replenishing the medium, to achieve biofilm maturation. This process was repeated at the beginning of each treatment run. The model has been validated previously. 31, 32 Susceptibility of S. aureus to rifampicin (Rifadin infusion; Sanofi-Aventis, NJ, USA) and clindamycin (clindamycin hydrochloride; Fluka Analytical, Buchs, Switzerland) and of P. aeruginosa to gentamicin (gentamicin sulphate; Sigma-Aldrich, St Louis, MO, USA) and ciprofloxacin (ciprofloxacin hydrochloride; PanReac AppliChem, St Louis, MO, USA) was carried out in accordance with EUCAST guidelines 33 and verified before each treatment by Etest (bioMérieux, Craponne, France).
Potential antibiotic enhancers
The concentrations of the antibiotic enhancers were determined by the literature review, using achievable, non-toxic plasma levels as a marker of safe levels (irrespective of the intended local application) of those that can be administered systemically 10, [18] [19] [20] 22, [28] [29] [30] as a guide. The following putative antibiotic enhancers were tested in the biofilm model: NAC (neutralized with sodium hydroxide), acetylsalicylic acid, sodium salicylate, salicylic acid (all Sigma-Aldrich), rhDNase I (Dornase alpha; Genentech, CA, USA), dispersin B (Kane Biotech, Winnipeg, Manitoba, Canada), hydrogen peroxide (Scientific Laboratory Supplies, Nottingham, UK) and JBS (formulation sold in England; Johnson & Johnson, New Brunswick, NJ, USA). NAC was neutralized because it is neutralized for clinical use in solutions given orally and for injection. Two different concentrations of each enhancer were examined in the experiments, with the chosen high and low concentrations added to the biofilm model shown in Table 1 .
JBS ingredients
Surfactants, preservatives and dyes in JBS were investigated for their antibiofilm activity. The surfactants investigated were sodium lauryl ether sulphate (SLES) (Mistral R&D Laboratories, Antrim, Northern Ireland), sodium lauroamphoacetate (SLAA) (Colonial Chemical Inc., Pittsburg, TN, USA), polysorbate 20 (Sigma-Aldrich), polyethylene glycol 80 (PEG-80) [Tween 28-LQ-(CQ); Croda International Plc, Snaith, UK] and polyethylene glycol distearate (PEG-150) (Evonik Industries, Essen, Germany). The preservatives were sodium benzoate and citric acid and the dyes were quinolone yellow (all Sigma-Aldrich) and sunset yellow FCF (Sigma-Aldrich).
Preliminary screening for antibacterial activity was determined by broth microdilution based on EUCAST guidance. 33 Briefly, the JBS ingredient and JBS stock solutions were sterilized by autoclaving or membrane filtration. Bacteria were grown overnight on blood agar and a 0.5 McFarland suspension (spectrophotometrically adjusted) in PBS was prepared postincubation. In triplicate, 100 lL of cation-adjusted Mueller-Hinton broth (MHB; Sigma-Aldrich) was added to each well in the 12 rows on a 96-well plate (Nunclon Delta Surface; Thermo Scientific, Roskilde, Denmark). To the first wells 100 lL of the drug standard was added, mixed and 100 lL was transferred to the next well. The final well contained only MHB. To all wells including the MHB-only well, 10 lL of the bacterial suspension was added. The plates were incubated overnight at 37 C. For preliminarily screening for the possible antibiotic-enhancing activity of the ingredients, JBS, the individual ingredients and antibiotics were tested in combination in a modified chequerboard assay. 34 A 1:100 dilution of a 0.5 McFarland bacterial suspension in PBS was determined to be equivalent to 5%10 5 cfu/mL for both bacteria. According to the MICs determined in the broth microdilution assay, a 4%MIC stock solution of each JBS ingredient was prepared and sterilized accordingly. A stock solution (8%MIC) of each antibiotic was prepared. To a 96-well plate, 100 lL of MHB was added to each well. The JBS ingredient was serially diluted along the y-axis with a starting concentration of 2%MIC. The two antibiotics were serially diluted along the x-axis, with 50 lL of each antibiotic stock solution added to the initial wells also to give a starting concentration of 2%MIC. All wells were inoculated with 10 lL of the bacterial suspension. JBS ingredients showing potential antibacterial activity and/or interaction with the antibiotics were tested in the biofilm model at high (10%MIC) and low (1%MIC) concentrations.
Treatment of mature biofilm
After incubation of the silicone discs for 5 days, the TSB was removed and replaced with 1.0 mL of fresh TSB plus any treatment. The treatment Belfield et al.
groups were: no treatment, 10%MIC alone, 100%MIC alone, low concentration potential antibiotic enhancer alone and paired with 10%MIC and 100%MIC, and high concentration potential antibiotic enhancer (Table 1) alone and paired with 10%MIC and 100%MIC. Experiments were performed in triplicate with an additional set of three prepared for resuscitation experiments if necessary. Where biofilms had apparently been eradicated, a further period of antibiotic-free incubation was applied to detect any sublethal suppression. Treatment was for either 7 or 14 days. Dispersin B was tested only against S. aureus, as its enzymatic activity is directed against N-acetyl glucosamine and not the P. aeruginosa exopolysaccharide matrix. At the end of treatment, any surviving bacteria were quantified. Discs were removed and placed into sterile 1.5 mL microtubes (Sarstedt, Nümbrecht, Germany) with 400 lL of 10% trypsin (gamma-irradiated; SAFC Biosciences, Hampshire, UK), which disaggregated bacteria attached to the disc. Microtubes were incubated for 15 min at 37 C, trypsin was replaced with 1.0 mL of PBS and all tubes were sonicated (30 kHz) for 5 min to detach bacteria from the disc. Previous work showed that trypsinization and sonication together yielded more bacteria than each separately without loss of viability. 32 The sonicate was serially diluted and 200 lL of the dilutions was spread on each of three blood agar plates (Oxoid) and incubated for 48 h at 37 C.
Resuscitation experiments
Plates were checked for growth after 24 h. If two or more of the three plates were culture negative after 48 h, resuscitation experiments were undertaken to determine if the treatment had killed the bacteria (resuscitation negative, indicating biofilm eradication) or merely inhibited growth (resuscitation positive, indicating biofilm suppression). Discs were washed in 1.0 mL of PBS and placed into 1.0 mL of fresh TSB to provide optimum growth conditions for 6 days to revive any bacteria with suppressed growth. The attached bacteria were quantified as described previously.
Determining development of resistance after treatment
Colonies that grew after 14 days of treatment or were culture-negative after 14 days of treatment but then resuscitation-positive had their MICs determined again by Etest. If small colony variants (SCVs) 35 were present alongside typical colonies, each population had their MIC determined separately. Isolates from biofilms that were not eradicated after 14 days were also investigated for resistance using EUCAST breakpoints.
Scanning electron microscopy (SEM)
Five day old biofilms on silicone discs were fixed in 1.0 mL of cold acetone, dried with tetramethylsilane (Sigma-Aldrich), sputter coated with gold for 300 s and then visualized using Jeol 6060LV variable pressure SEM (Jeol UK Ltd).
Statistics
The effect of antibiotics and antibiotic enhancers between groups was compared using two-way ANOVA (Graphpad Prism 7.01, La Jolla, CA, USA). Twoway ANOVA was conducted on the effect of the concentration of antibiotics and the antibiotic enhancer on reduction of biofilm bacteria (cfu/mL). Post hoc multiple comparisons were only carried out when the ANOVA value was significant (P , 0.05) and was corrected using Dunnett's test.
Results
Susceptibility to the chosen antibiotics 
Confirmation of biofilm growth in model
S. aureus and P. aeruginosa appeared structurally as biofilms on SEM. In Figure 1(b) , the bacteria are more difficult to distinguish as so much polysaccharide extracellular matrix was produced that the bacteria were incompletely exposed. The discs were confirmed to be colonized with 10 8 cfu/mL after sonication. S. aureus and P. aeruginosa both behaved functionally as biofilms in that neither was eradicated with 14 days of treatment with 10%MIC or 100%MIC antibiotics alone, although antibiotics reduced the number of viable bacteria present.
Treatment of mature biofilms with antibiotics alone or in combination with potential antibiotic enhancers Mature biofilms of S. aureus or P. aeruginosa were treated with paired antibiotics, with a potential antibiotic enhancer or with antibiotics and the enhancers together. The results of 14 day treatments of the two biofilms are shown in Figure 2 . For S. aureus, the main effect of antibiotic concentration (including no antibiotics) was statistically significant at P , 0.0001 and the main effect of different antibiotic enhancers was statistically significant at P , 0.0001 (Figure 2a) . Likewise, the main effect of antibiotic concentration was significant (P " 0.0005) for P. aeruginosa and the Anti-biofilm enhancers JAC main effect of different antibiotic enhancers was significant at P , 0.0001 (Figure 2b ). Biofilm eradication and inhibition were considered as the most stringent measures of efficacy rather than bacterial count reduction. JBS was the only potential antibiotic enhancer capable of eradicating both S. aureus and P. aeruginosa biofilms. Ten per cent JBS in combination with 10%MIC antibiotics and 100%MIC antibiotics eradicated S. aureus biofilms in 14 days. JBS appeared to enhance the activity of antibiotics against the mature staphylococcal biofilm as 10%MIC and 100%MIC antibiotics without JBS were insufficient to eradicate or inhibit biofilm. Ten per cent JBS in combination with 100%MIC antibiotics eradicated the pseudomonas biofilm and was the only treatment to do so.
Hydrogen peroxide (3%) alone and paired with antibiotics was capable of eradicating the S. aureus biofilm after 14 days of treatment. Hydrogen peroxide with 10%MIC and 100%MIC inhibited the P. aeruginosa biofilm after 14 days, but did not eradicate it. rhDNase I (100 mg/L) alone significantly (P , 0.0001) reduced staphylococcal biofilm bacteria, but did not enhance the activity of the antibiotics. rhDNase I in combination with 100%MIC inhibited P. aeruginosa biofilm after 14 days of treatment, but did not eradicate it.
Development of resistance
The majority of biofilms were not eradicated by 100%MIC concentrations of antibiotics. As the sub-minimum biofilm eradication concentration levels can result in resistance in the surviving isolates, MICs for those that survived treatment from each of the assays, including SCV populations, were determined.
Resistance to rifampicin developed in 7 (6.1%) of the 114 S. aureus 14 day surviving or 14 day resuscitated isolates tested. Of these seven, two were categorized as SCVs and six were isolates that had been resuscitated. None developed resistance to clindamycin. Of the 126 P. aeruginosa survivors four (3.2%) developed resistance to gentamicin and one developed resistance to ciprofloxacin. The five resistant P. aeruginosa survivors had all been treated with 10%MIC and rhDNase I, and four were SCVs. Of these, three were resistant to gentamicin and one to ciprofloxacin. None was resistant to both antibiotics.
Screening of ingredients in JBS for antibacterial activity
These results suggest that JBS may be the most promising antibiofilm agent and potential antibiotic enhancer determined by this systematic comparison. However, JBS is a complex mixture of ingredients (Table 2 ). To determine the active anti-biofilm component of JBS, its ingredients were screened for antibacterial activity and interaction with antibiotics and those of interest were tested in the biofilm model.
The MIC of several of the ingredients was greater than any concentrations tested. Therefore, these ingredients were not tested for interaction in the chequerboard assay as they did not demonstrate an antibacterial effect at a concentration within the range of concentrations used in commercially available topical antiseptic solutions.
Chequerboard assay to determine interaction of JBS ingredients with antibiotics
Initially the pairs of antibiotics were screened for their drug interaction, defined as the fractional inhibitory concentration index Log cfu/mL (mean + SD) for 5 day old P. aeruginosa (a) and S. aureus (b) biofilms treated for 14 days with antibiotic enhancer and/or antibiotics (10%MIC or 100%MIC antibiotics). Antibiotics against P. aeruginosa were ciprofloxacin and gentamicin and the antibiotics against S. aureus were rifampicin and clindamycin. Asterisk indicates 'inhibited', meaning that treatment resulted in bacterial counts of zero but resuscitation experiments were positive for bacterial growth, whereas plus symbol indicates 'eradicated', meaning that treatment resulted in bacterial counts of zero and remained negative for growth after resuscitation experiments.
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(FICI) where FICI 0.5 indicates synergy, FICI .4.0 indicates antagonism and values in between suggest no interaction. 36 The FICI between gentamicin and ciprofloxacin against P. aeruginosa was 0.0625 indicating synergy (Table 3) .
Biofilm model
SLAA and SLES were tested in the biofilm model (Figure 3) . Quinolone yellow and sunset yellow were excluded as they were antagonistic when paired with antibiotics in the chequerboard assay against S. aureus. JBS was run alongside SLAA and SLES for consistency with the original experiment, and with 100%MIC antibiotics was able to eradicate mature P. aeruginosa and S. aureus biofilms after 14 days. SLAA paired with 10%MIC antibiotics was able to eradicate P. aeruginosa and S. aureus biofilms demonstrating an enhancing effect as 10%MIC alone was not capable of eradicating either biofilm.
Discussion
In this study, several literature-cited potential antibiotic enhancers were systematically evaluated against S. aureus and P. aeruginosa mature biofilm models. When used alone hydrogen peroxide and rhDNase 1 demonstrated a significant anti-biofilm effect against S. aureus (P , 0.001 and P , 0.001, respectively) when compared with the untreated control. Therefore, it was not possible to demonstrate potentiation of antibiotic activity for these two agents. However, 10% JBS acted as an antibiotic enhancer in combination with 10%MIC, eradicating both S. aureus and P. aeruginosa biofilms with no recovery where both 10%MIC and 100%MIC antibiotics alone failed to eradicate these biofilms. When the individual ingredients of the successful JBS were investigated, SLAA showed the greatest anti-biofilm activity as it was able to eradicate S. aureus and P. aeruginosa biofilm in 14 days with 10%MIC and 100%MIC antibiotics.
Biofilm model
The in vitro biofilm model, validated in previous studies, 32 and was chosen for its ability to provide individual experimental conditions for each biofilm grown on a silicone disc. A 5 day old biofilm was considered mature and well-established based on our previous studies, which demonstrated that 1 day old biofilms were easier to eradicate than 5 day old ones (data not shown), consistent with the findings of Anwar et al., 37 who showed that mature S. aureus biofilms are more difficult to treat with antibiotics than younger biofilms. Two antibiotics were used together according to the dual drug principle, which states that using two antibiotics of two different classes at concentrations above their MIC reduces the risk of the development of resistance. 38 rhDNase I rhDNase cleaves bacterial extracellular DNA (eDNA), a component of the biofilm matrix. 19 However, it did not reduce pseudomonas biofilm when used alone. The role of eDNA varies between organisms. It is required only for initial biofilm formation of P. aeruginosa, 39 but it plays a more important structural role in established S. aureus biofilms compared with Staphylococcus epidermidis biofilms. 21 When Whitchurch et al. 39 treated a 5 day old pseudomonas biofilm with DNase I it disrupted the biofilm, but not a 7 day old biofilm. Our results differ from the Whitchurch et al. 39 study only in that our 5 day old biofilm was not affected by rhDNase I alone, possibly due to strain differences as we used a clinically isolated strain and they used P. aeruginosa PA01, a common research strain.
Izano et al. 21 demonstrated that the exopolysaccharide matrix and eDNA have different structural roles in S. aureus and S. epidermidis biofilms, where eDNA had a more major role in the S. aureus biofilm structure. This was shown by action of rhDNase I, which inhibited biofilm formation and detached pre-formed S. aureus biofilms, but not S. epidermidis biofilms. Our results are consistent with Izano et al. 21 as 100 mg/L rhDNase I reduced biofilm in our pre-formed S. aureus biofilm model. 
JAC
Hydrogen peroxide
Hydrogen peroxide eradicated staphylococcal biofilm at 7 days (data not shown), alone and in combination with 100%MIC antibiotics. However, it inhibited pseudomonas biofilms only when paired with 100%MIC antibiotics. Suman et al. 22 found that hydrogen peroxide had an 'inhibitory effect' on 37 biofilm organisms that they tested and they demonstrated that its effectiveness against a broad spectrum of microorganisms unlike dispersin B and other enzymes. Toté et al. 40 found that hydrogen peroxide was active against P. aeruginosa and S. aureus biofilm bacteria as well as the biofilm matrix. S. aureus and P. aeruginosa are catalasepositive organisms. Eradication of the biofilm may be a mechanical action in which bubbling physically disrupts the structure or a chemical action in which the molecule itself reacts with a component of the biofilm.
JBS
JBS has been proposed as an adjuvant treatment in chronic rhinosinusitis, 23 a biofilm infection, as it contains three surfactants, which have also been shown to disrupt biofilms in orthopaedic infections. 41 JBS is well-tolerated by users and is non-irritant. Chiu et al. 23 found that 10% JBS alone was not capable of eradicating an established pseudomonas biofilm, which concurs with our results. However, JBS with 100%MIC antibiotics did eradicate pseudomonas biofilm in our study and was the only treatment to do so. Furthermore, JBS with 10%MIC antibiotics also eradicated the staphylococcal biofilm and was in fact the only treatment able to eradicate biofilm with antibiotic levels as low as this. Antibiotics alone at 10%MIC did not eradicate an established biofilm. It therefore appears that JBS enhanced the activity of the antibiotics. An antibiotic level of 10%MIC is readily achievable by local administration without toxicity, making JBS the most promising agent tested in these experiments.
From the results, it is clear that SLAA is most likely responsible. Alone, it recreates the same antibiotic-enhancing effect demonstrated by JBS. SLAA is an amphoteric surfactant, with limited data demonstrating some antibacterial activity; 42, 43 however, to our knowledge, this is the first study to show the anti-biofilm activity of SLAA. Amphoteric compounds, being both anionic and cationic, have an advantage in that they have both the detergent activity seen with anionic compounds and the bactericidal activity seen with cationic compounds. 44 In the case of biofilm bacteria, it is possible that the detergent activity physically disrupts the biofilm and the bactericidal activity of SLAA and the antibiotics together can then be effective against newly planktonic cells.
Conclusions and implications for practice
Based on the results, JBS (in particular, the SLAA component), rhDNase I and hydrogen peroxide might have a role in local therapy for local biofilm conditions such as OME, osteomyelitis or infection of accessible implantable devices. In any situation where a local infection may be treated with antibiotic beads or in which the infected area may be irrigated with an antibiotic solution, the enhancer could be added alongside. Irrigation of infected wounds is common practice and antibiotics or antiseptics may be added to the irrigation fluid. 45 Considering the high acceptability of JBS in both medical use and for its original, intended hair shampoo use, that rhDNase I is approved for use in the lungs by inhalation, 46 and that hydrogen peroxide has many historical antiseptic uses, these three agents are likely to have satisfactory safety profiles. Furthermore, success in this experimental setting was considered complete eradication of biofilm, but in vivo a significant reduction in bacterial counts might be considered a success in certain Figure 3 . Log cfu/mL (mean + SD) for 5 day old P. aeruginosa (a) and S. aureus (b) biofilms treated for 14 days with JBS ingredients and/or antibiotics (10%MIC or 100%MIC antibiotics). Antibiotics against P. aeruginosa were ciprofloxacin and gentamicin and the antibiotics against S. aureus were rifampicin and clindamycin. Asterisk indicates 'inhibited', meaning that treatment resulted in bacterial counts of zero but resuscitation experiments were positive for bacterial growth, whereas plus symbol indicates 'eradicated', meaning that treatment resulted in bacterial counts of zero and remained negative for growth after resuscitation experiments.
circumstances. It is accepted that the results of in vitro evaluations do not always apply in vivo; nevertheless, we feel that on safety and in vitro grounds the enhancers show clinical promise. Future in vivo studies are planned to look at JBS or its active component, SLAA, as an adjunct to local antibiotic treatment for infections such as otitis externa, OME and infected wounds.
